Explorer les evidences

76 %Among children who were unsuppressed at baseline, three-month multimonth dispensing (3MMD) was associated with a 76% higher likelihood of viral suppression (adjusted risk ratio 1.76, 95% CI: 1.30–2.37).

KenyaVIH/sidapublié 2024Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 8 observations

0,23 per_100_person-yearsHIV incidence was 0.23 per 100 person-years postpartum.

KenyaVIH/sidapublié 2022Global health, science and practicePubMeddocument de 3 observations

11 %La fréquence de la neuropathie chez les personnes vivant avec le VIH au Kenya était de 11 % en 2011.

KenyaVIH/sidaobservé 2011HAL · Unilimdocument de 747 observations

6 %Between May 1, 2018, and March 31, 2020, 1910 out of 32,722 female individuals tested positive for HIV in western Kenya, representing a prevalence of 6% among those receiving HIV testing services.

KenyaVIH/sidaobservé May 1, 2018 to March 31, 2020publié 2023The Lancet. Global healthPubMeddocument de 11 observations

4,52 odds_ratioAdjusted odds of viral failure were higher for guidelines-unsupported versus supported regimens (OR = 4.52; 95% CI 1.02–26.24).

KenyaVIH/sidapublié 2025Journal of the International AIDS SocietyPubMeddocument de 15 observations

71 %Among 358 partner participants who knew they were HIV positive, 358 (71%) were virally suppressed.

KenyaVIH/sidapublié 2024The Lancet. Global healthPubMeddocument de 7 observations

2,11 timesAfter adjusting for age and individual-level risk factors, HIV prevalence was 2.11 times higher among nonvenue adolescent girls and young women not engaged in sex work compared with venue-based adolescent girls and young women not engaged in sex work in Mombasa, Kenya.

KenyaVIH/sidapublié 2024Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 6 observations

46 %Among 437 pregnant women living with HIV in western Kenya, 46% disclosed their HIV status to a relative.

KenyaVIH/sidapublié 2020BMC pregnancy and childbirthPubMeddocument de 11 observations

74 %Among 54 children with 560 viral load visits followed from 48 to 96 months, five viral load trajectory groups were identified: sustained-low (74%), mid-range (4%), periods-of-low (7%), high-to-low (7%), and sustained-high (7%).

KenyaVIH/sidapublié 2024Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 5 observations

1,9 timesOver 3 years, the risk of HIV acquisition was 1.9 times higher in those living ≥ 1 month outside their community in the past 12 months compared to those who had not.

KenyaVIH/sidapublié 2025AIDS and behavioreurope_pmcdocument de 18 observations

99 %Among 1743 female partners of male partners (FPPs) reporting a prior HIV diagnosis, 99% were on antiretroviral treatment (ART) at baseline.

KenyaVIH/sidaobservé 2018 to 2022publié 2024Journal of the International AIDS SocietyPubMeddocument de 10 observations

7,69 odds_ratioHIV-1 seropositive women were nearly 8 times as likely to have genital warts compared with HIV-1-seronegative women, with an odds ratio of 7.69.

Kenyagenital warts · VIH/sidaobservé 2001-2007publié 2012Sexually transmitted diseaseseurope_pmcdocument de 3 observationsDOI 10.1097/olq.0b013e318275ec7f

123 casesHIV genotyping was successful for 123 out of 124 prevalent cases and all 21 seroconverters.

KenyaVIH/sidapublié 2021Clinical infectious diseases : an official publication of the Infectious Diseases Society PubMeddocument de 6 observations

300 IC(50)Elite neutralizer activity is defined as the ability to neutralize, on average, more than one pseudovirus at an IC(50) titer of 300 within a clade group and across at least four clade groups.

KenyaVIH/sidapublié 2009Journal of virologyeurope_pmcdocument de 2 observationsDOI 10.1128/jvi.00110-09

4,8 %In the BREATHER Plus trial, the estimated probability of confirmed HIV-1 RNA ≥50 copies per mL by week 96 was 4.8% in the continuous ART group.

KenyaVIH/sidapublié 2026The lancet. HIVPubMeddocument de 10 observations

0,92 aRRInternalized HIV stigma was independently associated with lower likelihood of successful completion of PMTCT (adjusted risk ratio 0.92; 95% confidence interval 0.88–0.98).

KenyaVIH/sidaobservé 2017publié 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 4 observations

9,7 %Among 3152 participants who inject drugs in Kenya, 306 (9.7%) were HIV-positive.

KenyaVIH/sidapublié 2025The International journal on drug policyPubMeddocument de 6 observations

37 900 000 inhabitantsGlobally, people infected with HIV/AIDS were estimated to be 37.9 million in 2018.

KenyaVIH/sidaobservé 2018publié 2020African Journal of Health SciencesOpenAlexdocument de 7 observations

5 %At week 48, 5.0% of participants in the dolutegravir group met the primary end point of plasma HIV type 1 RNA level of at least 50 copies per milliliter.

KenyaVIH/sidaobservé week 48publié 2023The New England journal of medicinePubMeddocument de 8 observations

25 %Among 1,384 young adults living with HIV in Western Kenya, the prevalence of lifetime violence was 25% in male patients under 20 years.

KenyaVIH/sidapublié 2026The Journal of the Association of Nurses in AIDS Care : JANACPubMeddocument de 8 observations

4,9 %HIV prevalence rate in Kenya was 4.9% among the general population aged 15–64 years.

KenyaVIH/sidapublié 2020African Journal of Health SciencesOpenAlexdocument de 7 observations

68 %68% of women agreed that their male partner would want to receive text messages during PMTCT care.

KenyaVIH/sidapublié 2021AIDS carePubMeddocument de 7 observations

1 813 individualsAmong children and adolescents living with HIV in central Kenya, 1,813 (37.7%) were enrolled at WHO stage II disease.

KenyaVIH/sidapublié 2022AIDS research and human retrovirusesPubMeddocument de 18 observations

89 %Point-of-care viral load testing uptake was high (>89%) throughout pregnancy, delivery, and postpartum periods.

KenyaVIH/sidapublié 2023Journal of the International AIDS SocietyPubMeddocument de 8 observations

52 %More than half (52%) of mortality among HIV-positive tuberculosis patients was ascribed to advanced HIV disease.

Kenyatuberculose · VIH/sidapublié 2023African health sciencesPubMeddocument de 6 observations